Loading...
OTCM
IVRO
Market cap1mUSD
Jul 01, Last price  
0.09USD
Name

Invitro International

Chart & Performance

D1W1MN
OTCM:IVRO chart
P/E
15.57
P/S
2.16
EPS
0.01
Div Yield, %
Shrs. gr., 5y
0.28%
Rev. gr., 5y
-4.47%
Revenues
879k
+8.34%
1,300,0001,300,000500,0001,400,0001,900,0001,700,0001,100,0001,100,000686,118994,714884,245855,615846,3351,052,7371,104,8161,003,403853,511792,628811,290878,937
Net income
122k
+14.32%
100,000100,000-3,500,000-5,100,000-3,700,000-4,400,000-2,800,000-1,900,00027,186232,100122,90347,83556,40970,67349,89495,99221,2761,553106,704121,980
CFO
-7k
L
-2,000,000-4,000,000-3,500,000-3,100,000-2,700,000-1,800,00047,916242,236164,58018,53361,280137,723-22,37831,98740,624-59,11198,598-7,283

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1985 and headquartered in Placentia, California, InVitro International specializes in creating and supplying non-animal testing kits to markets both within the United States and globally. Key among their offerings is the Irritection Assay System, an in vitro diagnostic tool designed to identify, categorize, and forecast the potential for eye and skin irritation across a broad spectrum of items, including cosmetics, general consumer products, pharmaceuticals, and various chemical raw materials. They also provide Corrositex, another in vitro test specifically for determining chemical corrosiveness. Beyond product sales, the company delivers tailored technological support for the implementation and use of the Irritection system, alongside offering independent laboratory services for irritation and corrosion assessments. Their solutions are predominantly adopted by manufacturers involved in producing surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials.
IPO date
May 16, 1991
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT